当前位置:首页 - 行情中心 - 江中药业(600750) - 财务分析 - 利润表

江中药业

(600750)

  

流通市值:141.55亿  总市值:141.97亿
流通股本:6.27亿   总股本:6.29亿

利润表

报告期2024-12-312024-09-302024-06-302024-03-31
公司类型通用通用通用通用
一、营业总收入4,435,450,590.732,971,879,125.962,172,527,003.861,227,404,483.82
营业收入4,435,450,590.732,971,879,125.962,172,527,003.861,227,404,483.82
二、营业总成本3,461,306,482.832,215,871,404.321,596,488,140.46899,421,405.12
营业成本1,617,993,300.84960,827,878.54672,575,771.74383,292,218.02
税金及附加64,293,434.8845,306,073.4632,374,634.3917,708,509.11
销售费用1,494,915,537.251,055,073,662.22780,764,999.85451,228,957.44
管理费用228,997,968.8136,350,486.7886,537,186.6339,863,057.4
研发费用130,427,615.777,862,125.9965,053,345.4528,615,257.33
财务费用-75,321,374.64-59,548,822.67-40,817,797.6-21,286,594.18
其中:利息费用1,705,672.02251,878.63231,233.5116,803.02
其中:利息收入77,477,542.8360,125,118.1641,266,593.0421,410,096.41
加:公允价值变动收益-8,626,804.43844,285.11844,284.98620,293.38
加:投资收益-2,828,979.93-2,610,311.3-1,438,563.16-156,921.56
资产处置收益1,837,913.47-292,779.0970,261.643,743.8
资产减值损失(新)-16,072,851.21-8,039,897.43-7,606,008.65-8,220,500.98
信用减值损失(新)14,465,586.1823,030,379.1223,864,648.311,402,459.62
其他收益65,378,991.8337,912,830.8124,407,890.933,543,342.56
营业利润平衡项目0000
四、营业利润1,028,297,963.81806,852,228.86616,181,377.4335,215,495.52
加:营业外收入8,212,304.636,030,370.644,822,992.841,196,329.57
减:营业外支出10,897,474.645,319,029.771,164,611.75356,695.07
利润总额平衡项目0000
五、利润总额1,025,612,793.8807,563,569.73619,839,758.49336,055,130.02
减:所得税费用165,105,804.49123,670,699.1895,419,669.2751,509,994.17
六、净利润860,506,989.31683,892,870.55524,420,089.22284,545,135.85
持续经营净利润860,506,989.31683,892,870.55524,420,089.22284,545,135.85
归属于母公司股东的净利润788,192,557.44634,340,897.79488,753,443.17266,779,517.36
少数股东损益72,314,431.8749,551,972.7635,666,646.0517,765,618.49
(一)基本每股收益1.251.010.780.43
(二)稀释每股收益1.251.010.780.43
九、综合收益总额860,506,989.31683,892,870.55524,420,089.22284,545,135.85
归属于母公司股东的综合收益总额788,192,557.44634,340,897.79488,753,443.17266,779,517.36
归属于少数股东的综合收益总额72,314,431.8749,551,972.7635,666,646.0517,765,618.49
公告日期2025-03-202024-10-262024-08-222024-04-27
审计意见(境内)标准无保留意见
TOP↑